• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Estrofem 1, 2 mg
    / Novo Nordisk


    Active Ingredient
    Estradiol 1 mg, 2 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Film Coated Tablets

    28 X 1 mg

    partial basket chart 24680 5160

    Film Coated Tablets

    28 X 2 mg

    not in the basket chart 8782 5075

    Related information


    Dosage

    Estrofem is an oestrogen-only product for hormonal replacement. Estrofem is administered orally, one tablet daily without interruption. For initiation and continuation of treatment of menopausal symptoms, the lowest effective dose for the shortest duration should be used.
    A switch to a higher dose or a lower dose of Estrofem could be indicated if the response after three months is insufficient for satisfactory symptom relief or if the tolerability is not satisfactory.
    In women without a uterus, Estrofem may be started on any convenient day. In women with a uterus who present amenorrhoea and are being transferred from a sequential HRT, Estrofem may be initiated on day 5 of bleeding and only in combination with a progestagen for at least 12–14 days; if transferred
    from a continuous-combined HRT, Estrofem along with a progestin, may be started on any convenient day. The progestagen type and dose should provide sufficient inhibition of the oestrogen induced endometrial proliferation.
    If the patient has forgotten to take a tablet, the tablet should be taken as soon as possible within the next 12 hours. If more than 12 hours have passed, the tablet should be discarded. Forgetting a dose for women with a uterus may increase the likelihood of breakthrough bleeding and spotting.
    Unless there is a previous diagnosis of endometriosis, it is not recommended to add a progestagen in hysterectomised women.


    Indications

    Estrogen deficiency, especially after hysterectomy, prevention of bone mineral loss in post-menopausaul women.


    Contra-Indications

    See prescribing information for full details.


    Special Precautions

    See prescribing information for full details.


    Side Effects

    See prescribing information for full details.


    Drug interactions

    Barbiturates, carbamazepine, dichloralphenazone, griseofulvin, phenytoin, primidone, rifampicin. Coumarin anticoagulants, bile acids, antihypertensives, diuretics, topical corticosteroids.


    Manufacturer
    Novo Nordisk A/S, Denmark
    Licence holder
    CLOSE